121 related articles for article (PubMed ID: 7539736)
1. [Established oneself the detection of serum prostate specific antigen and application in clinical practice].
Feng T; Dou CQ; Xia TL
Zhonghua Wai Ke Za Zhi; 1994 Nov; 32(11):685-7. PubMed ID: 7539736
[TBL] [Abstract][Full Text] [Related]
2. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
4. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
[TBL] [Abstract][Full Text] [Related]
5. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
6. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
7. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
8. [The percentage of free prostate specific antigen used in detecting prostate cancer].
Yang L; Fang Z; Song J; Deng S
Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
[TBL] [Abstract][Full Text] [Related]
9. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
10. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
11. Prostate tissue and serum markers.
Mazzucchelli R; Colanzi P; Pomante R; Muzzonigro G; Montironi R
Adv Clin Path; 2000 Jul; 4(3):111-20. PubMed ID: 11080790
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
Chakrabarti S; Raha K; Bhunia CL; Bhattachary DK
J Indian Med Assoc; 2001 Nov; 99(11):627-8, 630. PubMed ID: 12022203
[TBL] [Abstract][Full Text] [Related]
13. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
14. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
15. [Clinical assessment of free serum prostate specific antigen (PSA)].
Chautard D; Daver A; Bali B; Dardari J; Debras B; Colls P; Soret JY
Prog Urol; 1996 Jun; 6(3):368-74. PubMed ID: 8763691
[TBL] [Abstract][Full Text] [Related]
16. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
Abrahamsson PA; Kuriyama M
Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
[TBL] [Abstract][Full Text] [Related]
17. Total and free PSA: a methodical and clinical evaluation of five assays.
Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
[TBL] [Abstract][Full Text] [Related]
18. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
20. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
